Unraveling FAM221B: A Potential Drug Target and Biomarker (G392307)

Target Name: FAM221B

NCBI ID: G392307

FAM221B

Unraveling FAM221B: A Potential Drug Target and Biomarker

Introduction

FAM221B, a 22kDa hydrophobic glycoprotein, is upregulated in a variety of cancers. At the same time, its expression is down-regulated in various diseases, such as neurodegenerative diseases, diabetes and obesity. FAM221B is also associated with several diseases and drug targets, such as Parkinson's disease, Alzheimer's disease and chemotherapy drugs. Therefore, FAM221B is regarded as a potential drug target and biomarker.

Biological functions of FAM221B

FAM221B is a glycoprotein that plays multiple biological functions on the cell membrane. FAM221B is up-regulated in a variety of cell types and down-regulated in a variety of diseases. Its expression is up-regulated in neurodegenerative diseases, diabetes and obesity, while its expression is down-regulated in the immune system, inflammation and tumorigenesis.

Glycosylation status of FAM221B

The glycosylation status of FAM221B is up-regulated in various diseases. For example, in patients with Parkinson's disease, the glycosylation level of FAM221B is up-regulated, while it is down-regulated in normal subjects. In patients with Alzheimer's disease, the glycosylation level of FAM221B is also upregulated. These changes in glycosylation status may be related to disease development and treatment response.

Interaction of FAM221B with drug targets

FAM221B is associated with multiple drug targets. For example, FAM221B is associated with Parkinson's disease drugs such as levodopa, carbidopa, and alsulitan. FAM221B has also been linked to diabetes and obesity treatments such as metformin, glaqidone and orlistat. Therefore, FAM221B can be studied as a drug target or biomarker for these diseases.

Clinical application prospects of FAM221B

FAM221B is a potential drug target and biomarker. Studying the biological function, glycosylation status and interaction with drug targets of FAM221B may provide new ideas and strategies for the treatment of these diseases. For example, drugs targeting FAM221B can improve the treatment of diseases such as Parkinson's disease, Alzheimer's disease, and diabetes, or use FAM221B as a biomarker to predict disease risk and disease progression.

Conclusion

FAM221B is a potential drug target and biomarker. By studying the biological function, glycosylation status and interaction with drug targets of FAM221B, new ideas and strategies can be provided for the treatment of neurodegenerative diseases, diabetes, obesity and other diseases. FAM221B may also become an important drug target or biomarker for studying the efficacy and toxic side effects of drugs.

Protein Name: Family With Sequence Similarity 221 Member B

The "FAM221B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM221B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets